Witzig TE, Tomblyn MB, Misleh JG, Kio EA, Sharkey RM, Wegener WA, Goldenberg DM. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica 2014; 99(11):1738-1745; https://doi.org/10.3324/haematol.2014.112110.